Project Grant R01HL183124
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $827K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90502, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $718,824 in project grant funding (R01HL188006) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the mechanisms by which electronic cigarette exposure drives vascular injury and atherosclerosis progression through the glutamate N-methyl-D-aspartate receptor (NMDAR) pathway in vascular smooth muscle cells. The research comprises three...
- The National Heart, Lung, and Blood Institute awarded the University of California, Davis $770,045 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate tobacco smoke-driven fibroblast reprogramming in pulmonary fibrosis. The research deciphers molecular mechanisms by which tobacco smoke promotes fibrotic remodeling in the lungs. Using proteomic and metabolomic profiling, the investigator identified tobacco smoke–induced lactate accumulation and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $127,168 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model the effect of apolipoprotein L1 risk variants on cardiovascular disease risk in African American e-cigarette users. The research employs human induced pluripotent stem-cell-derived endothelial cells to investigate how e-cigarettes, with and without menthol, affect endothelial health in...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $778,127 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL180797) to enhance lamellar body function via LRRK2 inhibition and reduce respiratory distress syndrome severity in preterm newborns. The research investigates leucine-rich repeat kinase 2 (LRRK2) inhibition as a novel therapeutic approach to enhance endogenous surfactant production in...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $852,908 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to determine the effects of prenatal tetrahydrocannabinol (THC) exposure on offspring lung development and function. The award funds basic and translational research examining how chronic prenatal THC exposure affects fetal and infant respiratory health. Using rhesus macaque models, the research will evaluate...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $821,294 to The Trustees of Columbia University in the City of New York on September 1, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077, Project Grant R01HL179303). The award funds the VAPESCAN study, a longitudinal investigation examining early lung toxicity associated with e-cigarette versus cigarette use in young adults aged 18–50....